Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 655 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $320.33, for a total value of $209,816.15. Following the sale, the senior vice president now directly owns 11,803 shares in the company, valued at approximately $3,780,854.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Charles Dadswell also recently made the following trade(s):
- On Friday, November 1st, Charles Dadswell sold 193 shares of Illumina stock. The stock was sold at an average price of $297.28, for a total value of $57,375.04.
NASDAQ ILMN traded down $3.29 on Wednesday, hitting $319.68. 704,593 shares of the stock were exchanged, compared to its average volume of 1,017,568. Illumina, Inc. has a 52-week low of $263.30 and a 52-week high of $380.76. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15. The company has a market capitalization of $47.15 billion, a price-to-earnings ratio of 55.89, a P/E/G ratio of 2.37 and a beta of 1.06. The company’s 50-day moving average price is $307.27 and its two-hundred day moving average price is $310.18.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.53. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The firm had revenue of $907.00 million for the quarter, compared to analysts’ expectations of $872.65 million. During the same period in the previous year, the company posted $1.52 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that Illumina, Inc. will post 6.45 EPS for the current fiscal year.
ILMN has been the topic of several recent analyst reports. Wolfe Research set a $380.00 target price on Illumina and gave the stock a “buy” rating in a report on Friday, October 25th. ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a report on Tuesday. Argus boosted their target price on Illumina from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Guggenheim assumed coverage on shares of Illumina in a research report on Friday, October 25th. They issued a “buy” rating and a $350.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Illumina in a research report on Thursday, November 14th. They issued a “buy” rating and a $345.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Illumina has an average rating of “Buy” and an average target price of $333.50.
Large investors have recently modified their holdings of the business. Next Capital Management LLC acquired a new stake in shares of Illumina during the 2nd quarter valued at $25,000. Massey Quick Simon & CO. LLC lifted its position in Illumina by 3,100.0% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 93 shares during the last quarter. North Star Investment Management Corp. acquired a new position in Illumina during the 3rd quarter worth $31,000. Trustcore Financial Services LLC acquired a new position in Illumina during the 2nd quarter worth $44,000. Finally, Trust Co. of Vermont lifted its position in Illumina by 296.8% during the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 92 shares during the last quarter. 91.77% of the stock is owned by institutional investors.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.